is the leading manufacturer of Covid vaccines in America, and has recently began to rollout to rollout what many believe to be the most effective antiviral pill available to treat the virus as well.The rollout of both has already led to a substantial financial windfall for the New York City-based company, and the prospect on enhanced distribution of Paxlovid, the potential rollout of Omicron-tailored vaccines and more booster shots in the future will lead to an influx of even more cash.On Tuesday, the company revealed its Q4 earnings and revenue projections for 2022. The company estimates to rake in up to $102 billion in sales next year, which would be a new record.
Load More
Load More